CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Clinical trials for CARCINOMA, NON-SMALL-CELL LUNG (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, NON-SMALL-CELL LUNG (NSCLC) trials appear
Sign up with your email to follow new studies for CARCINOMA, NON-SMALL-CELL LUNG (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New lung cancer drug shows promise in early trial
Disease control Recruiting nowThis study tests a new medicine called PF-08634404, given alone or with chemotherapy, for adults with early or locally advanced non-small cell lung cancer. The trial has three parts: before surgery, after surgery if cancer remains, or after chemoradiation. Researchers will check …
Matched conditions: CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New lung cancer combo aims to beat current standard
Disease control Recruiting nowThis study tests whether a new experimental drug called PF-08634404, given with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to rec…
Matched conditions: CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo aims to boost lung cancer treatment
Disease control Recruiting nowThis Phase 3 trial tests whether adding Sigvotatug Vedotin to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has high levels of PD-L1. About 714 participants will receive either the combinati…
Matched conditions: CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Antidepressant may ease brain fog from lung cancer drug
Symptom relief Recruiting nowThis study tests whether vortioxetine, an antidepressant known to boost thinking skills, can reduce the mental fogginess caused by the lung cancer drug lorlatinib. About 24 adults with advanced ALK-positive lung cancer who are already taking lorlatinib will receive vortioxetine. …
Matched conditions: CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
PET scans may reveal early if immunotherapy works for lung cancer
Knowledge-focused Recruiting nowThis study is testing whether special PET scans can predict early on if immunotherapy (with or without chemotherapy) is working in people with advanced non-small cell lung cancer. Researchers will scan 200 patients before treatment, then at 6 and 12 weeks, looking for signs that …
Matched conditions: CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC